Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Solon Eiendom ASA in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.40.
Current Consensus is
The current consensus among 0 investment analysts is to n/a stock in Solon Eiendom ASA. This N/A consensus rating has held steady for over two years.
Solon Eiendom ASA acquires, develops, and sells residential real estate properties in Norway. The company was formerly known as Bionor Pharma ASA and changed its name to Solon Eiendom ASA. The company was founded in 2006 and is based in Oslo, Norway. Solon Eiendom ASA is a subsidiary of SamhÃ¤llsbyggnadsbolaget i Norden AB (publ). As on January 20, 2022, Solon Eiendom ASA was taken private.